Pimobendan study outcome – a ‘revolution’ for vet cardiology

Nov 13, 2017

A product that delays onset of congestive heart failure (CHF) in dogs by 15 months offers a “paradigm shift” in the way vets diagnose and treat myxomatous mitral valve disease (MMVD). Boehringer Ingelheim, the company behind pimobendan drug Vetmedin, cautiously estimated 7.5% of all dogs would suffer heart disease in their lifetimes, with MMVD its most prevalent form. Vetmedin was already licensed for the treatment of canine CHF from dilated cardiomyopathy or valvular insufficiency, as well as for treatment of cardiomyopathy in the preclinical stage in Dobermann pinschers. However, following the largest clinical trial in veterinary cardiology, the product can now be used by vets to treat the preclinical stage of MMVD, delaying onset of the clinical symptoms of heart failure. At an official launch for the European veterinary press, held in Frankfurt and attended by Veterinary Times, it was noted up to 40 million dogs worldwide could now benefit with treatment from pimobendan. The evaluation of pimobendan in dogs with cardiomegaly (EPIC) study set out to analyse whether long-term... ...

Read More